SGEP exits YPrime

Flexpoint Ford has made an investment in Malvern, Pennsylvania-based YPrime, a provider of clinical trials software. No financial terms were disclosed. As a result of the transaction, Stonehenge Growth Equity Partners has exited its investment in YPrime.



Stonehenge Growth Equity Partners (SGEP) today announced a third successful exit in the clinical trials software market, as the SGEP portfolio company YPrime, Inc. received a significant growth investment led by Flexpoint Ford (Flexpoint), a Chicago-based private equity firm focused on the healthcare and financial services industries.

Founded in 2006 and headquartered in Malvern, Pa., YPrime provides software and consulting services to create more efficient collaboration during clinical trials, including data collection and information management for biopharmaceutical companies and research organizations developing new medicines. Stonehenge invested in YPrime in 2017 and is celebrating a successful exit from that transaction. Financial terms of the YPrime transaction were not disclosed.

“YPrime was at a key moment when additional capital could help scale continued adoption by marquee customers,” said Travis Milks, a Managing Partner at SGEP and previous YPrime board member. “We were thrilled to support that growth, and we congratulate YPrime and Flexpoint on starting this new chapter. New technology, software and services are transforming how emerging therapies are developed, and we believe this industry will continue to experience significant growth.”

Based in Tampa, SGEP has been investing in growth-stage technology-enabled businesses since 1999 by developing trusted relationships with experienced entrepreneurs. SGEP supports portfolio companies through the most dynamic phases of their lifecycles, particularly where an entrepreneur is applying proven technology to solve a business problem. YPrime marks the third such successful investment in the clinical trials industry. Other investments include:

— Medidata Solutions, a provider of integrated software applications and services for the clinical research industry. It offers the Medidata Clinical Cloud, a platform, pioneering analytics, and clinical technology for the development of new therapies.

— iCardiac Technologies, a leading provider of centralized cardiac safety and respiratory solutions that accelerate clinical research. Stonehenge exited its investment in iCardiac when Norwest Venture Partners acquired a controlling interest in the spring of 2014.

“SGEP brings a team approach to investments by partnering with portfolio companies,” said Brian Model, a Managing Partner with SGEP who led the company’s prior investments in Medidata Solutions and iCardiac Technologies. “We work to add value with strong industry investment experience, and by providing advice and key relationships that help our portfolio companies make significant advancements towards their next stage of growth.”

About Stonehenge Growth Equity Partners
Since 1999, the team at Stonehenge Growth Equity Partners (SGEP) has been investing in growth stage businesses. By developing trusted relationships with experienced entrepreneurs, SGEP supports its portfolio companies through the most dynamic phases of their lifecycles. Based in Tampa, FL, SGEP invests in companies where an entrepreneur is applying proven technology to solve a business problem. These technology-enabled businesses typically generate at least $3M of revenue and are profitable. Our target investment size is $1M to $5M in each portfolio company.

For more information, visit

About YPrime
YPrime offers more than a decade of focused work with eClinical systems to expedite and improve the quality of site and patient management, clinical supplies, drug accountability and clinical data. Cloud-based eCOA and IRT platforms enable greater speed, precision and integration in clinical trial management. Data services tools eliminate data silos and help sponsors bring together fragmented clinical research data into contextual and actionable information.

For more information, visit